A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
This is a phase III clinical trial to evaluate the efficacy and safety of SHR6390 in combination with Fulvestrant versus placebo combined with Fulvesrant in Patients who have HR positive and HER2 negative recurrent/metastatic breast cancer and have received prior endocrine therapy are eligible for study.
Advanced Breast Cancer
DRUG: SHR6390|DRUG: Placebo|DRUG: Fulvestrant
Investigator-assessed PFS, Investigator-assessed Progression Free Survival, Up to approximately 24 months.
Progression-free Survival (PFS) per RECIST 1.1, PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurs first., Up to approximately 24 months.|OS, Overall Survival, Up to approximately 2 years|ORR, Objective Response Rate, Up to approximately 24 months.|DoR, Duration of Objective Response, Up to approximately 24 months|CBR, Clinical Benefit rate, Up to approximately 24 months.|AEs and SAEs, Number of Participants With adverse events (AEs) and serious adverse events (SAEs) Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v4.03., Up to approximately 24 months.|Ctrough, Ctrough, Up to 4 weeks
This is a phase III clinical trial to evaluate the efficacy and safety of SHR6390 in combination with Fulvestrant versus placebo combined with Fulvesrant in Patients who have HR positive and HER2 negative recurrent/metastatic breast cancer and have received prior endocrine therapy are eligible for study.